非小细胞-话题@MedSci

#非小细胞#

746篇内容 | 6347人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2060141, encodeId=967e2060141d6, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Radiology：术前FDG PET/CT的应用对非小细胞肺癌患者的价值, objectType=article, longId=739485, objectId=63fae39485b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63fae39485b1, replyNumber=0, likeNumber=71, createdTime=2022-09-22, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63fae39485b1, moduleTitle=Radiology：术前FDG PET/CT的应用对非小细胞肺癌患者的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63fae39485b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060104, encodeId=16bf2060104d9, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, objectType=article, longId=301715, objectId=f4ef301e1547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ef301e1547, replyNumber=0, likeNumber=123, createdTime=2022-12-06, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ef301e1547, moduleTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ef301e1547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060075, encodeId=abe820600e59a, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=非小细胞肺癌，国内外治疗方案大比拼（2022.1版）, objectType=article, longId=292833, objectId=c17f29283359, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c17f29283359, replyNumber=0, likeNumber=79, createdTime=2022-12-05, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c17f29283359, moduleTitle=非小细胞肺癌，国内外治疗方案大比拼（2022.1版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c17f29283359)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060133, encodeId=6dba20601337c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=《围手术期非小细胞肺癌国际专家诊疗共识》即将重磅发布, objectType=article, longId=734893, objectId=70c5e348934b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70c5e348934b, replyNumber=0, likeNumber=74, createdTime=2023-03-04, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70c5e348934b, moduleTitle=《围手术期非小细胞肺癌国际专家诊疗共识》即将重磅发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70c5e348934b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060134, encodeId=86f4206013412, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=NCCN第三版非小细胞肺癌治疗指南出炉！国际前沿治疗局势一览, objectType=article, longId=735146, objectId=13bbe35146c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13bbe35146c3, replyNumber=0, likeNumber=118, createdTime=2023-06-06, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13bbe35146c3, moduleTitle=NCCN第三版非小细胞肺癌治疗指南出炉！国际前沿治疗局势一览, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13bbe35146c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060097, encodeId=7cb1206009e1b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Transl Lung Cancer Res: 那武利尤单抗联合重组人内皮抑素治疗既往经治晚期非小细胞肺癌的安全性和有效性, objectType=article, longId=300900, objectId=9658300900a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9658300900a6, replyNumber=0, likeNumber=130, createdTime=2022-05-21, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9658300900a6, moduleTitle=Transl Lung Cancer Res: 那武利尤单抗联合重组人内皮抑素治疗既往经治晚期非小细胞肺癌的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9658300900a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060096, encodeId=4e7d206009630, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=研究性癌症疫苗BNT116联合Libtayo (cemiplimab) 治疗非小细胞肺癌, objectType=article, longId=300372, objectId=d6ea3003e273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6ea3003e273, replyNumber=0, likeNumber=151, createdTime=2022-09-01, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6ea3003e273, moduleTitle=研究性癌症疫苗BNT116联合Libtayo (cemiplimab) 治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6ea3003e273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060136, encodeId=0b722060136f6, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=非小细胞肺癌九大靶点用药全梳理, objectType=article, longId=736230, objectId=3f8de362301f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f8de362301f, replyNumber=0, likeNumber=85, createdTime=2023-05-08, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f8de362301f, moduleTitle=非小细胞肺癌九大靶点用药全梳理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f8de362301f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060137, encodeId=2fbd206013e9f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, objectType=article, longId=736795, objectId=5afee36795cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5afee36795cd, replyNumber=0, likeNumber=106, createdTime=2023-08-06, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5afee36795cd, moduleTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5afee36795cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060088, encodeId=bedf2060088fd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=295679, objectId=7f802956e901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f802956e901, replyNumber=0, likeNumber=71, createdTime=2022-12-25, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f802956e901, moduleTitle=Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f802956e901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060123, encodeId=f791206012375, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, objectType=article, longId=727507, objectId=8299e27507ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8299e27507ba, replyNumber=0, likeNumber=109, createdTime=2023-05-05, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8299e27507ba, moduleTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8299e27507ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060113, encodeId=637f206011316, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=89, createdTime=2022-09-02, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060131, encodeId=151c20601312c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=实用干货：早中晚各阶段非小细胞肺癌放疗方案汇总, objectType=article, longId=730494, objectId=1ecde304948e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ecde304948e, replyNumber=0, likeNumber=95, createdTime=2022-07-04, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ecde304948e, moduleTitle=实用干货：早中晚各阶段非小细胞肺癌放疗方案汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ecde304948e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060080, encodeId=86ec20600807b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐, objectType=article, longId=294781, objectId=1a2d294e81fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a2d294e81fd, replyNumber=0, likeNumber=79, createdTime=2022-12-05, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a2d294e81fd, moduleTitle=非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a2d294e81fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060118, encodeId=5216206011857, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Nat Cancer：JBJ-09-063：非小细胞肺癌治疗的潜在EGFR变构抑制剂, objectType=article, longId=725549, objectId=d86fe255493e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d86fe255493e, replyNumber=0, likeNumber=0, createdTime=2023-03-05, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d86fe255493e, moduleTitle=Nat Cancer：JBJ-09-063：非小细胞肺癌治疗的潜在EGFR变构抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d86fe255493e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060110, encodeId=88eb20601104f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Cancer：韩国多中心真实世界研究评估晚期或转移性非小细胞肺癌（NSCLC）免疫治疗的长期临床预后：KCSG LU20-11, objectType=article, longId=723574, objectId=fef6e2357411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef6e2357411, replyNumber=0, likeNumber=85, createdTime=2022-11-08, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef6e2357411, moduleTitle=Cancer：韩国多中心真实世界研究评估晚期或转移性非小细胞肺癌（NSCLC）免疫治疗的长期临床预后：KCSG LU20-11, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef6e2357411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060069, encodeId=cf8820600692b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, objectType=article, longId=259943, objectId=cceb25994367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cceb25994367, replyNumber=0, likeNumber=69, createdTime=2022-01-22, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cceb25994367, moduleTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cceb25994367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060083, encodeId=2255206008302, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=295269, objectId=bfe4295269f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfe4295269f7, replyNumber=0, likeNumber=0, createdTime=2022-08-09, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfe4295269f7, moduleTitle=Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfe4295269f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060068, encodeId=0aca206006808, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效, objectType=article, longId=221635, objectId=7c93221635a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c93221635a0, replyNumber=0, likeNumber=92, createdTime=2022-01-23, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c93221635a0, moduleTitle=Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c93221635a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060092, encodeId=675320600925a, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, objectType=article, longId=299456, objectId=55f52994568e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55f52994568e, replyNumber=0, likeNumber=98, createdTime=2022-08-17, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55f52994568e, moduleTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55f52994568e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非小细胞

2020-05-29

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Radiology：术前FDG PET/CT的应用对非小细胞肺癌患者的价值

2022-09-22

智慧医人 (审核中...)

前往app查看评论内容

#非小细胞#

ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）

2022-12-06

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

非小细胞肺癌，国内外治疗方案大比拼（2022.1版）

2022-12-05

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

《围手术期非小细胞肺癌国际专家诊疗共识》即将重磅发布

2023-03-04

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

NCCN第三版非小细胞肺癌治疗指南出炉！国际前沿治疗局势一览

2023-06-06

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Transl Lung Cancer Res: 那武利尤单抗联合重组人内皮抑素治疗既往经治晚期非小细胞肺癌的安全性和有效性

2022-05-21

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

研究性癌症疫苗BNT116联合Libtayo (cemiplimab) 治疗非小细胞肺癌

2022-09-01

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

非小细胞肺癌九大靶点用药全梳理

2023-05-08

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）

2023-08-06

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效

2022-12-25

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究

2023-05-05

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-09-02

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

实用干货：早中晚各阶段非小细胞肺癌放疗方案汇总

2022-07-04

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐

2022-12-05

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Nat Cancer：JBJ-09-063：非小细胞肺癌治疗的潜在EGFR变构抑制剂

2023-03-05

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Cancer：韩国多中心真实世界研究评估晚期或转移性非小细胞肺癌（NSCLC）免疫治疗的长期临床预后：KCSG LU20-11

2022-11-08

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理

2022-01-22

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效

2022-08-09

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效

2022-01-23

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异

2022-08-17

科室
- - 订阅+
  - 更多科室
工具
服务